SlideShare a Scribd company logo
NEOPLASIA
Characteristics/ Classification of
Neoplasms
Dr. S. Parasuraman
Senior Lecturer
Faculty of Pharmacy
Definition
that
• Neoplasia means ‘new growth’
• Neoplasm means ‘tumour/ cancer’
• Cancer is an uncontrolled proliferation of cells
express varying degree of fidelity to their precursors.
• It can be benign or malignant.
• Benign: Cells grow as a compact
mass and remain at their site of
origin
• Malignant:
Growth of cells is uncontrolled
Cells can spread into surrounding
tissue and spread to distant sites.
Cellular adaptations
Cellular adaptations
• Atrophy: Reduction of number and size of parenchymal cells
of an organ or its parts which was once normal is called
atrophy. E.g.: ischemic atrophy, neuropathic atrophy.
• Hypertrophy: Increase is an size of parenchymal cells resulting
in enlargement of the organ. E.g.: enlarged size of uterus in
pregnancy (physiological), hypertrophy of cardiac muscle
(pathological).
Cellular adaptations
• Hyperplasia: Increased number of parenchymal cells resulting
in enlargement of the organ. E.g.: Hyperplasia of female
breast at puberty, pregnancy and lactation
during
(physiological), wound healing (pathological; formation of
granulation tissue due to proliferation of fibroblasts and
endothelial cells)
• Dysplasia: Disordered cellular development (pleomorphism,
nuclear hyperchromasia, mitosis, loss of polarity)
accompanied with metaplasia and hyperplasia.
• Metaplasia: Reversible changes in one type of epithelial or
epithelial or
mesenchymal adult cell to another type of
mesenchymal adult cell .
– Epithelial  Squamous and Columnar metaplasia
– Mesenchymal  Osseous and Cartilaginous metaplasia
Differences between normal and
cancer cell
Differences between benign and
malignant neoplasms
Differences between benign and
malignant neoplasms
BENIGN MALIGNANT
Nuclear variation in
size and shape
minimal
Nuclear variation in size and
shape minimal to marked,
often variable
Diploid Range of ploidy
Low mitotic count,
normal mitosis
Low to high mitotic count,
abnormal mitosis
Retention of
specialisation
Loss of specialisation
Structural
differentiation
retained
Structural differentiation shows
wide range of changes
Organised Not organised
Functional
differentiation
usually
Functional differentiation often
lost
Causes of cancer
Three major type of carcinogens
Chemical carcinogenesis
• Mutagens
• Chemical carcinogenesis and their metabolism
Physical carcinogenesis (radiation)
• Ultraviolet radiation, Asbestos
Infectious Pathogens (Viral)
• Human T-cell leukemia viruses, DNA
viruses, Human papillomaviruses
• Epstein-Barr virus, Hepatitis B virus
Development of cancer
• Changes in DNA (mutation)
• The change must cause an alteration in cell growth and behaviour
• The change must be non-lethal and be passed onto daughter cells
• Alterations in more than one gene
• Genes concerned are oncogenes/tumour suppressor genes
• Sequence of gene alterations from normal to benign to malignant
• Intrinsic and extrinsic / inheritance and environment key factors
Possible events
Benign
Dysplasia
In-situ
Invasive
Invasive
Invasive
Invasive
Dysplasia
Dysplasia In-situ
In-situ
Benign
Benign
Benign
Benign
Dysplasia
In-situ
Invasive
Properties of cancer cells
• Tow unique properties of cancer cells are
– ability to invade locally
– capacity to metastasize to distant sites to distant sites – cancer
spreading (patterns of spread)
Patterns of spread:
Direct extension: Carcinomas begin as
localized growths (direct seeding of body
cavities or surface), when they arise. In
early cancers do not penetrate the
basement membrane (carcinoma in situ).
When the in situ tumor acquires invasive
potential extends directly to compromise
neighboring cells and to metastasize. E.g.
Peritoneal carcinomatosis (metastatic
ovarian carcinoma)
Properties of cancer cells
• Patterns of spread:
– Direct extension
– Metastatic spread: Transfer of
malignant cells from one site to
another (not directly connected
with it). Invasive properties of
malignant tumors bring them into
contact with blood and lymphatic
vessels.
• Hematogenous metastases
• Lymphatic metastases
Nomenclature
• Benign tumors:
– Suffix- oma to cell of origin
– Name of origin cell + morphologic
pailoma, ovarian cyst adenoma)
character + oma (skin
– E.g.:
• tumors of squamous epithelium- epithelioma
• tumors arising from the glandular gland (colon/ endocrine glands)-
adenoma
– lipoma ,fiboma, chondroma, osteoma papilloma
Nomenclature
• Malignant tumors:
– mesenchymal tissue are usually called sarcoma
– Epithelial cell origin are usually called carcinoma
– Name of origin cell + morphologic character + carcinoma/
sarcoma
– E.g.:
• Malignant tumor of the stomach is a gastric adenocarcinoma or
adenocarcinoma of the stomach.
Special nomenclature
• Blastoma: tumors rigging in immature tissue or nervous
tissue, most of them are malignant
– E.g.: medulloblastoma, retinoblastoma, nephroblastoma
• Some tumors ataching the suffix- oma, but they are malignant
Malignant tumor of the liver: Hepatoma
Melanoma of the skin: Seminoma
Lymphoproferative tumor: Lymphoma (Hodgkin’s and non Hodgkin’s)
Malignant proliferation of leukocytes: Leukemia
Special nomenclature
• Mixed tumors: Derived from one from one germ layer
may undergo divergent defferentiation creating
– E.g.: Mixed tumor of salivary gland
• Teratomas: Tumors containing mature or immature cells
• Hamartoma: tumor-like malformation composed of a
haphazard arrangement of tissues indigenous to the
particular site, which is totally benign.
Classification of tumours
Tissue or origin Benign Malignant
Epithelial tumours
1. Squamous epithelium Squamous cell papilloma Squamous cell carcinoma
2. Transitional epithelium Transitional cell papilloma Transitional cell
carcinoma
3. Glandular epithelium Adenoma Adenocarcinoma
4. Basal cell layer skin -- Basal cell carcinoma
5. Neuroectoderm Naevus Melanoma
(melanocarcinoma)
6. Hepatocytes Liver cell adenoma Hepatoma
(Hepatocellular
carcinoma)
7. Placenta (chorionic
epithelium)
Hydatidiform mole Choriocarcinoma
Classification of tumours
Tissue or origin Benign Malignant
Non-epithelial (mesenchymal) tumours
1. Adipose tissue Lipoma Liposarcoma
2. Adult fibrous tissue Fibroma Fibrosarcoma
3. Embryonic fibrous
tissue
Myxoma Myxosarcoma
4. Cartilage Chondroma Chondrosarcoma
5. bone Osteoma Osteosarcoma
6. Synovium Benign synovioma Synovial sarcoma
7. Smooth muscle Leiomyoma Leiomyosarcoma
8. Embryonic fibrous
tissue
Rhabdomyoma Rhabdomysarcoma
Classification of tumours
Tissue or origin Benign Malignant
Non-epithelial (mesenchymal) tumours
9. Mesothelium -- Mesothelioma
10. Blood vessels Haemangioma Angiosarcoma
11. Lymph vessels Lymphangioma Lymphangiosarcoma
12. Glomus Glomus tumour --
13. Meninges Meningioma Invasive meningioma
14. Haematopoietic cells -- Leukaemias
15. Lymphoid tissue Pseudolymphoma Malignant lymphomas
16. Nerve sheath Neurilemmoma,
Neurofibroma
Neurogenic sarcoma
17. Nerve cells Ganglioneuroma Neuroblastoma
Classification of tumours
Tissue or origin Benign Malignant
Mixed Tumours
Salivary glands Pleomorphic adenoma Malignant mixed salivary
tumour
Tumours of more than one germ cell layer
Totipotent cells in gonads
or in embryonal rests
Mature teratoma Immature teratoma
Characteristics of tumours
• Majority of neoplasms can be categorized clinically and
morphological into benign and malignant on the basis of
certain characteristics listed bellow
– Rate of growth
– Cancer phenotype and stem cells
– Clinical and gross features
– Microscopic features
– Local invasion (direct spread)
– Metastasis (distant spread)
Characteristics of tumours
• Rate of growth
– The tumour cell proliferate more rapidly than the normal cells.
– The tumour enlarge rate is depends upon
1. Rate of cell production, growth fraction and rate of cell loss
2. Degree of differentiation of the tumour
1. Rate of growth of a tumour depends upon
• Doubling time (mitotic rate) of tumour cells
• Number of cells remaining in preoperative pool (growth fraction)
• Rate of loss of tumour cells by cell shedding
Cancer cell do not follow the normal cell controls in cells, and are immortal.
The cell division rate is high and center of tumor do not receive adequate
nourishment and undergo ischemic necrosis, loss shedding.
Death tumour cells appear as apoptotic figures and dividing tumours are
seen as normal/ abnormal mitotic figure ultimately tumour grow in size.
Characteristics of tumours
• Rate of growth
2. Degree of differentiation
• Rate of growth of malignant tumour is directly proportionate to the
degree of differentiation.
• Poorly differentiated tumours show aggressive growth pattern
compare to better differentiated tumours.
• Rarely, a malignant tumour may disappear spontaneously from the
primary site, due to good host immune attack.
Characteristics of tumours
• Cancer phenotype and stem cells
Cancer cells
1. disobey the growth control – proliferate rapidly
2. escape from death signals – immortality
3. imbalance between cell proliferation and cell death – excessive growth
4. lose differentiation properties – no function
5. are unstable – newer mutations
6. overrun their neighboring tissue – invade locally
7. have the ability to travel from the site of origin to other part of body –
distant metastasis
Cancer stem cells/ tumour-initiating cells have the properties of self-renewal,
asymmetric replication and transdifferentiation (i.e. plasticity).
Characteristics of tumours
• Clinical and gross features
– Benign tumour are generally slow growing and depending
upon location remains asymptomatic (subcutaneous lipoma)
or may cause serous symptoms (meningioma in the nervous
system). Benign tumours are generally spherical or ovoid
shape.
– Malignant tumor grow rapidly, invade locally into deeper
tissue and spread to distant sites (metastasis). Malignant
tumours are usually irregular in shape, poor-circumscribed
and extend into adjacent tissues.
Characteristics of tumours
• Microscopic features
– Microscopic pattern
– Cytomorphology of neoplastic cells
– Tumor angiogenesis and stroma
– Inflammatory reaction
Characteristics of tumours
• Local invasion (direct spread)
– Benign: expand and push aside without invading, infiltrating
or metastasising.
– Malignant: expand, invasion, infiltration and destruction of
the surrounding tissue.
• Metastasis (distant spread)
– Metastasis (meta= transformation, stasis= residence): spread
of tumour by invasion.
– Routes of metastasis
• Lymphatic spread
• Haematogenous spread
• Spread along body cavities and natural passages
Tumours grading
Grading is based on (1) the degree of anaplasia
(2) the rate of growth
• Grade-I : Well-differentiated (less than 25% anaplastic cells)
• Grade-II : Moderately-differentiated (25-50% anaplastic cells)
• Grade-III : Moderately-differentiated (50-75% anaplastic cells)
• Grade-IV : Poorly-differentiated or anaplastic (more than 75%
anaplastic cells)
Tumours staging
• International TNM system is commonly used for solid
tumours (less applicable to lymphomas and leukaemias).
– T: Tumour (size of primary tumour), N: Nodes (local/ regional
node involvement), M: Metastases (distant metastases)
T0 No evidence of tumour N0 Regional lymph nodes not involved
Tis Carcinoma in situ NX Regional lymph nodes can’t be
assessed
TX Tumour can’t be
assessed
N1-4 Progressive increase in number of
local/ regional lymph nodes involved
T1-4 Progressive increase in
tumour size
M0 No evidence of distant metastases
MX distant metastases can’t be assessed
M1-3 Increasing involvement of distant
metastases
Thank you
Epithelial tissues
Mesebchymal tissues

More Related Content

Similar to Type of Tumors بلال العميسي( مختبرات طبية).pptx

01 NEOPLASIA.pptx
01 NEOPLASIA.pptx01 NEOPLASIA.pptx
01 NEOPLASIA.pptx
RahmatGul12
 
Neoplasia 2018.ppt
Neoplasia 2018.pptNeoplasia 2018.ppt
Neoplasia 2018.ppt
kevin90931
 
Neoplasia
NeoplasiaNeoplasia
Neoplasia
Sumanvijyanta
 
Neoplasia: Nomenclature, Staging and Grading
Neoplasia: Nomenclature, Staging and GradingNeoplasia: Nomenclature, Staging and Grading
Neoplasia: Nomenclature, Staging and Grading
Oluwatobi Olusiyan
 
Neoplasia introduction
Neoplasia introductionNeoplasia introduction
Neoplasia introduction
Prasad CSBR
 
Neoplasm - basic of oncology
Neoplasm - basic of oncologyNeoplasm - basic of oncology
Neoplasm - basic of oncology
Nahar Kamrun
 
neoplasia 1
 neoplasia  1 neoplasia  1
neoplasia 1
MINDS MAHE
 
Neoplasia
NeoplasiaNeoplasia
Neoplasia
Navisrani
 
Cancer
CancerCancer
Cancer
Arun Kumar
 
Oncology
OncologyOncology
Neoplasms
NeoplasmsNeoplasms
Neoplasms
NeoplasmsNeoplasms
Neoplasms
guestafb98a0
 
Pathology Lecture - Neoplasia
Pathology Lecture - NeoplasiaPathology Lecture - Neoplasia
Pathology Lecture - Neoplasia
Shashidhar Venkatesh Murthy
 
neoplasia.pptx
neoplasia.pptxneoplasia.pptx
neoplasia.pptx
Munmun Kulsum
 
Introduction to oncology
Introduction to oncologyIntroduction to oncology
Introduction to oncology
ABDUL QADEER MEMON
 

Similar to Type of Tumors بلال العميسي( مختبرات طبية).pptx (20)

01 NEOPLASIA.pptx
01 NEOPLASIA.pptx01 NEOPLASIA.pptx
01 NEOPLASIA.pptx
 
Neoplasia 2018.ppt
Neoplasia 2018.pptNeoplasia 2018.ppt
Neoplasia 2018.ppt
 
Neoplasia
NeoplasiaNeoplasia
Neoplasia
 
Neoplasia: Nomenclature, Staging and Grading
Neoplasia: Nomenclature, Staging and GradingNeoplasia: Nomenclature, Staging and Grading
Neoplasia: Nomenclature, Staging and Grading
 
Neoplasia introduction
Neoplasia introductionNeoplasia introduction
Neoplasia introduction
 
Neoplasia
NeoplasiaNeoplasia
Neoplasia
 
Neoplasm - basic of oncology
Neoplasm - basic of oncologyNeoplasm - basic of oncology
Neoplasm - basic of oncology
 
neoplasia 1
 neoplasia  1 neoplasia  1
neoplasia 1
 
Neoplasia
NeoplasiaNeoplasia
Neoplasia
 
Cancer
CancerCancer
Cancer
 
Oncology
OncologyOncology
Oncology
 
Neoplasms
NeoplasmsNeoplasms
Neoplasms
 
Neoplasms
NeoplasmsNeoplasms
Neoplasms
 
Cancer1
Cancer1Cancer1
Cancer1
 
Pathology Lecture - Neoplasia
Pathology Lecture - NeoplasiaPathology Lecture - Neoplasia
Pathology Lecture - Neoplasia
 
Cancer
CancerCancer
Cancer
 
neoplasia.pptx
neoplasia.pptxneoplasia.pptx
neoplasia.pptx
 
Introduction to oncology
Introduction to oncologyIntroduction to oncology
Introduction to oncology
 
Neoplasia
NeoplasiaNeoplasia
Neoplasia
 
neoplasia.pptx
neoplasia.pptxneoplasia.pptx
neoplasia.pptx
 

More from ssuser668f10

Urine and Stool analysis.ppt urine and stool analysis
Urine and Stool analysis.ppt urine and stool analysis Urine and Stool analysis.ppt urine and stool analysis
Urine and Stool analysis.ppt urine and stool analysis
ssuser668f10
 
Glossary_ST_NAR_26_A.pdf medical
Glossary_ST_NAR_26_A.pdf medical Glossary_ST_NAR_26_A.pdf medical
Glossary_ST_NAR_26_A.pdf medical
ssuser668f10
 
Blood cell morphology.ppt
Blood cell morphology.pptBlood cell morphology.ppt
Blood cell morphology.ppt
ssuser668f10
 
Practical 40 biochemical test microbiology.pdf
Practical 40 biochemical test microbiology.pdfPractical 40 biochemical test microbiology.pdf
Practical 40 biochemical test microbiology.pdf
ssuser668f10
 
5 Leukopoiesis (1).pdf
5                     Leukopoiesis (1).pdf5                     Leukopoiesis (1).pdf
5 Leukopoiesis (1).pdf
ssuser668f10
 
1-1.pdf
1-1.pdf1-1.pdf
1-1.pdf
ssuser668f10
 
biochemicalreactionsnew-190412162327.pdf
biochemicalreactionsnew-190412162327.pdfbiochemicalreactionsnew-190412162327.pdf
biochemicalreactionsnew-190412162327.pdf
ssuser668f10
 
الاحماض النوويه1.ppt
الاحماض النوويه1.pptالاحماض النوويه1.ppt
الاحماض النوويه1.ppt
ssuser668f10
 
ASO test.ppt
ASO test.pptASO test.ppt
ASO test.ppt
ssuser668f10
 
Clinical enzymology.ppt
Clinical enzymology.pptClinical enzymology.ppt
Clinical enzymology.ppt
ssuser668f10
 
جميل الغيثي.en.ar.pptx
جميل الغيثي.en.ar.pptxجميل الغيثي.en.ar.pptx
جميل الغيثي.en.ar.pptx
ssuser668f10
 
بكتيريا.en.ar.pptx
بكتيريا.en.ar.pptxبكتيريا.en.ar.pptx
بكتيريا.en.ar.pptx
ssuser668f10
 
cardiac_function_test_2018.ppt
cardiac_function_test_2018.pptcardiac_function_test_2018.ppt
cardiac_function_test_2018.ppt
ssuser668f10
 
Neutralization--TV (1).pptx
Neutralization--TV (1).pptxNeutralization--TV (1).pptx
Neutralization--TV (1).pptx
ssuser668f10
 
b.coli
b.colib.coli
b.coli
ssuser668f10
 
EpidemiologyOverview.ppt
EpidemiologyOverview.pptEpidemiologyOverview.ppt
EpidemiologyOverview.ppt
ssuser668f10
 
ANTI COAGULANT (2).pptx
ANTI COAGULANT (2).pptxANTI COAGULANT (2).pptx
ANTI COAGULANT (2).pptx
ssuser668f10
 
Carbohydrates Metabolism - Copy.pptx
Carbohydrates Metabolism - Copy.pptxCarbohydrates Metabolism - Copy.pptx
Carbohydrates Metabolism - Copy.pptx
ssuser668f10
 
1584610537.pptx
1584610537.pptx1584610537.pptx
1584610537.pptx
ssuser668f10
 
safety_chem_course_en.en.ar.pdf
safety_chem_course_en.en.ar.pdfsafety_chem_course_en.en.ar.pdf
safety_chem_course_en.en.ar.pdf
ssuser668f10
 

More from ssuser668f10 (20)

Urine and Stool analysis.ppt urine and stool analysis
Urine and Stool analysis.ppt urine and stool analysis Urine and Stool analysis.ppt urine and stool analysis
Urine and Stool analysis.ppt urine and stool analysis
 
Glossary_ST_NAR_26_A.pdf medical
Glossary_ST_NAR_26_A.pdf medical Glossary_ST_NAR_26_A.pdf medical
Glossary_ST_NAR_26_A.pdf medical
 
Blood cell morphology.ppt
Blood cell morphology.pptBlood cell morphology.ppt
Blood cell morphology.ppt
 
Practical 40 biochemical test microbiology.pdf
Practical 40 biochemical test microbiology.pdfPractical 40 biochemical test microbiology.pdf
Practical 40 biochemical test microbiology.pdf
 
5 Leukopoiesis (1).pdf
5                     Leukopoiesis (1).pdf5                     Leukopoiesis (1).pdf
5 Leukopoiesis (1).pdf
 
1-1.pdf
1-1.pdf1-1.pdf
1-1.pdf
 
biochemicalreactionsnew-190412162327.pdf
biochemicalreactionsnew-190412162327.pdfbiochemicalreactionsnew-190412162327.pdf
biochemicalreactionsnew-190412162327.pdf
 
الاحماض النوويه1.ppt
الاحماض النوويه1.pptالاحماض النوويه1.ppt
الاحماض النوويه1.ppt
 
ASO test.ppt
ASO test.pptASO test.ppt
ASO test.ppt
 
Clinical enzymology.ppt
Clinical enzymology.pptClinical enzymology.ppt
Clinical enzymology.ppt
 
جميل الغيثي.en.ar.pptx
جميل الغيثي.en.ar.pptxجميل الغيثي.en.ar.pptx
جميل الغيثي.en.ar.pptx
 
بكتيريا.en.ar.pptx
بكتيريا.en.ar.pptxبكتيريا.en.ar.pptx
بكتيريا.en.ar.pptx
 
cardiac_function_test_2018.ppt
cardiac_function_test_2018.pptcardiac_function_test_2018.ppt
cardiac_function_test_2018.ppt
 
Neutralization--TV (1).pptx
Neutralization--TV (1).pptxNeutralization--TV (1).pptx
Neutralization--TV (1).pptx
 
b.coli
b.colib.coli
b.coli
 
EpidemiologyOverview.ppt
EpidemiologyOverview.pptEpidemiologyOverview.ppt
EpidemiologyOverview.ppt
 
ANTI COAGULANT (2).pptx
ANTI COAGULANT (2).pptxANTI COAGULANT (2).pptx
ANTI COAGULANT (2).pptx
 
Carbohydrates Metabolism - Copy.pptx
Carbohydrates Metabolism - Copy.pptxCarbohydrates Metabolism - Copy.pptx
Carbohydrates Metabolism - Copy.pptx
 
1584610537.pptx
1584610537.pptx1584610537.pptx
1584610537.pptx
 
safety_chem_course_en.en.ar.pdf
safety_chem_course_en.en.ar.pdfsafety_chem_course_en.en.ar.pdf
safety_chem_course_en.en.ar.pdf
 

Recently uploaded

Cardiac Arrhythmias (2).pdf for nursing student
Cardiac Arrhythmias (2).pdf for nursing studentCardiac Arrhythmias (2).pdf for nursing student
Cardiac Arrhythmias (2).pdf for nursing student
fahmyahmed789
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Health Catalyst
 
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Guillermo Rivera
 
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
Dr Rachana Gujar
 
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)
blessyjannu21
 
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
o6ov5dqmf
 
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareStem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Dr. David Greene Arizona
 
Top massage center in ajman chandrima Spa
Top massage center in ajman chandrima  SpaTop massage center in ajman chandrima  Spa
Top massage center in ajman chandrima Spa
Chandrima Spa Ajman
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
Naeemshahzad51
 
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGYTime line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
DianaRodriguez639773
 
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DR Jag Mohan Prajapati
 
Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.
Dinesh Chauhan
 
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsxChild Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Sankalpa Gunathilaka
 
Nursing education curriculum development.pptx
Nursing education curriculum development.pptxNursing education curriculum development.pptx
Nursing education curriculum development.pptx
sadhanajagtap3
 
CMHPSM Regional Compliance Training 2024
CMHPSM Regional Compliance Training 2024CMHPSM Regional Compliance Training 2024
CMHPSM Regional Compliance Training 2024
JColaianne
 
Rate Controlled Drug Delivery Systems.pdf
Rate Controlled Drug Delivery Systems.pdfRate Controlled Drug Delivery Systems.pdf
Rate Controlled Drug Delivery Systems.pdf
Rajarambapu College of Pharmacy Kasegaon Dist Sangli
 
NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022
nktiacc3
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
Rommel Luis III Israel
 
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
The Lifesciences Magazine
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Rommel Luis III Israel
 

Recently uploaded (20)

Cardiac Arrhythmias (2).pdf for nursing student
Cardiac Arrhythmias (2).pdf for nursing studentCardiac Arrhythmias (2).pdf for nursing student
Cardiac Arrhythmias (2).pdf for nursing student
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
 
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
 
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
 
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)
 
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
 
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareStem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
 
Top massage center in ajman chandrima Spa
Top massage center in ajman chandrima  SpaTop massage center in ajman chandrima  Spa
Top massage center in ajman chandrima Spa
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
 
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGYTime line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
 
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
 
Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.
 
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsxChild Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
 
Nursing education curriculum development.pptx
Nursing education curriculum development.pptxNursing education curriculum development.pptx
Nursing education curriculum development.pptx
 
CMHPSM Regional Compliance Training 2024
CMHPSM Regional Compliance Training 2024CMHPSM Regional Compliance Training 2024
CMHPSM Regional Compliance Training 2024
 
Rate Controlled Drug Delivery Systems.pdf
Rate Controlled Drug Delivery Systems.pdfRate Controlled Drug Delivery Systems.pdf
Rate Controlled Drug Delivery Systems.pdf
 
NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
 
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
 

Type of Tumors بلال العميسي( مختبرات طبية).pptx

  • 1. NEOPLASIA Characteristics/ Classification of Neoplasms Dr. S. Parasuraman Senior Lecturer Faculty of Pharmacy
  • 2. Definition that • Neoplasia means ‘new growth’ • Neoplasm means ‘tumour/ cancer’ • Cancer is an uncontrolled proliferation of cells express varying degree of fidelity to their precursors. • It can be benign or malignant. • Benign: Cells grow as a compact mass and remain at their site of origin • Malignant: Growth of cells is uncontrolled Cells can spread into surrounding tissue and spread to distant sites.
  • 4. Cellular adaptations • Atrophy: Reduction of number and size of parenchymal cells of an organ or its parts which was once normal is called atrophy. E.g.: ischemic atrophy, neuropathic atrophy. • Hypertrophy: Increase is an size of parenchymal cells resulting in enlargement of the organ. E.g.: enlarged size of uterus in pregnancy (physiological), hypertrophy of cardiac muscle (pathological).
  • 5. Cellular adaptations • Hyperplasia: Increased number of parenchymal cells resulting in enlargement of the organ. E.g.: Hyperplasia of female breast at puberty, pregnancy and lactation during (physiological), wound healing (pathological; formation of granulation tissue due to proliferation of fibroblasts and endothelial cells) • Dysplasia: Disordered cellular development (pleomorphism, nuclear hyperchromasia, mitosis, loss of polarity) accompanied with metaplasia and hyperplasia. • Metaplasia: Reversible changes in one type of epithelial or epithelial or mesenchymal adult cell to another type of mesenchymal adult cell . – Epithelial  Squamous and Columnar metaplasia – Mesenchymal  Osseous and Cartilaginous metaplasia
  • 6. Differences between normal and cancer cell
  • 7. Differences between benign and malignant neoplasms
  • 8. Differences between benign and malignant neoplasms BENIGN MALIGNANT Nuclear variation in size and shape minimal Nuclear variation in size and shape minimal to marked, often variable Diploid Range of ploidy Low mitotic count, normal mitosis Low to high mitotic count, abnormal mitosis Retention of specialisation Loss of specialisation Structural differentiation retained Structural differentiation shows wide range of changes Organised Not organised Functional differentiation usually Functional differentiation often lost
  • 9. Causes of cancer Three major type of carcinogens Chemical carcinogenesis • Mutagens • Chemical carcinogenesis and their metabolism Physical carcinogenesis (radiation) • Ultraviolet radiation, Asbestos Infectious Pathogens (Viral) • Human T-cell leukemia viruses, DNA viruses, Human papillomaviruses • Epstein-Barr virus, Hepatitis B virus
  • 10. Development of cancer • Changes in DNA (mutation) • The change must cause an alteration in cell growth and behaviour • The change must be non-lethal and be passed onto daughter cells • Alterations in more than one gene • Genes concerned are oncogenes/tumour suppressor genes • Sequence of gene alterations from normal to benign to malignant • Intrinsic and extrinsic / inheritance and environment key factors
  • 12. Properties of cancer cells • Tow unique properties of cancer cells are – ability to invade locally – capacity to metastasize to distant sites to distant sites – cancer spreading (patterns of spread) Patterns of spread: Direct extension: Carcinomas begin as localized growths (direct seeding of body cavities or surface), when they arise. In early cancers do not penetrate the basement membrane (carcinoma in situ). When the in situ tumor acquires invasive potential extends directly to compromise neighboring cells and to metastasize. E.g. Peritoneal carcinomatosis (metastatic ovarian carcinoma)
  • 13. Properties of cancer cells • Patterns of spread: – Direct extension – Metastatic spread: Transfer of malignant cells from one site to another (not directly connected with it). Invasive properties of malignant tumors bring them into contact with blood and lymphatic vessels. • Hematogenous metastases • Lymphatic metastases
  • 14. Nomenclature • Benign tumors: – Suffix- oma to cell of origin – Name of origin cell + morphologic pailoma, ovarian cyst adenoma) character + oma (skin – E.g.: • tumors of squamous epithelium- epithelioma • tumors arising from the glandular gland (colon/ endocrine glands)- adenoma – lipoma ,fiboma, chondroma, osteoma papilloma
  • 15. Nomenclature • Malignant tumors: – mesenchymal tissue are usually called sarcoma – Epithelial cell origin are usually called carcinoma – Name of origin cell + morphologic character + carcinoma/ sarcoma – E.g.: • Malignant tumor of the stomach is a gastric adenocarcinoma or adenocarcinoma of the stomach.
  • 16. Special nomenclature • Blastoma: tumors rigging in immature tissue or nervous tissue, most of them are malignant – E.g.: medulloblastoma, retinoblastoma, nephroblastoma • Some tumors ataching the suffix- oma, but they are malignant Malignant tumor of the liver: Hepatoma Melanoma of the skin: Seminoma Lymphoproferative tumor: Lymphoma (Hodgkin’s and non Hodgkin’s) Malignant proliferation of leukocytes: Leukemia
  • 17. Special nomenclature • Mixed tumors: Derived from one from one germ layer may undergo divergent defferentiation creating – E.g.: Mixed tumor of salivary gland • Teratomas: Tumors containing mature or immature cells • Hamartoma: tumor-like malformation composed of a haphazard arrangement of tissues indigenous to the particular site, which is totally benign.
  • 18. Classification of tumours Tissue or origin Benign Malignant Epithelial tumours 1. Squamous epithelium Squamous cell papilloma Squamous cell carcinoma 2. Transitional epithelium Transitional cell papilloma Transitional cell carcinoma 3. Glandular epithelium Adenoma Adenocarcinoma 4. Basal cell layer skin -- Basal cell carcinoma 5. Neuroectoderm Naevus Melanoma (melanocarcinoma) 6. Hepatocytes Liver cell adenoma Hepatoma (Hepatocellular carcinoma) 7. Placenta (chorionic epithelium) Hydatidiform mole Choriocarcinoma
  • 19. Classification of tumours Tissue or origin Benign Malignant Non-epithelial (mesenchymal) tumours 1. Adipose tissue Lipoma Liposarcoma 2. Adult fibrous tissue Fibroma Fibrosarcoma 3. Embryonic fibrous tissue Myxoma Myxosarcoma 4. Cartilage Chondroma Chondrosarcoma 5. bone Osteoma Osteosarcoma 6. Synovium Benign synovioma Synovial sarcoma 7. Smooth muscle Leiomyoma Leiomyosarcoma 8. Embryonic fibrous tissue Rhabdomyoma Rhabdomysarcoma
  • 20. Classification of tumours Tissue or origin Benign Malignant Non-epithelial (mesenchymal) tumours 9. Mesothelium -- Mesothelioma 10. Blood vessels Haemangioma Angiosarcoma 11. Lymph vessels Lymphangioma Lymphangiosarcoma 12. Glomus Glomus tumour -- 13. Meninges Meningioma Invasive meningioma 14. Haematopoietic cells -- Leukaemias 15. Lymphoid tissue Pseudolymphoma Malignant lymphomas 16. Nerve sheath Neurilemmoma, Neurofibroma Neurogenic sarcoma 17. Nerve cells Ganglioneuroma Neuroblastoma
  • 21. Classification of tumours Tissue or origin Benign Malignant Mixed Tumours Salivary glands Pleomorphic adenoma Malignant mixed salivary tumour Tumours of more than one germ cell layer Totipotent cells in gonads or in embryonal rests Mature teratoma Immature teratoma
  • 22.
  • 23. Characteristics of tumours • Majority of neoplasms can be categorized clinically and morphological into benign and malignant on the basis of certain characteristics listed bellow – Rate of growth – Cancer phenotype and stem cells – Clinical and gross features – Microscopic features – Local invasion (direct spread) – Metastasis (distant spread)
  • 24. Characteristics of tumours • Rate of growth – The tumour cell proliferate more rapidly than the normal cells. – The tumour enlarge rate is depends upon 1. Rate of cell production, growth fraction and rate of cell loss 2. Degree of differentiation of the tumour 1. Rate of growth of a tumour depends upon • Doubling time (mitotic rate) of tumour cells • Number of cells remaining in preoperative pool (growth fraction) • Rate of loss of tumour cells by cell shedding Cancer cell do not follow the normal cell controls in cells, and are immortal. The cell division rate is high and center of tumor do not receive adequate nourishment and undergo ischemic necrosis, loss shedding. Death tumour cells appear as apoptotic figures and dividing tumours are seen as normal/ abnormal mitotic figure ultimately tumour grow in size.
  • 25. Characteristics of tumours • Rate of growth 2. Degree of differentiation • Rate of growth of malignant tumour is directly proportionate to the degree of differentiation. • Poorly differentiated tumours show aggressive growth pattern compare to better differentiated tumours. • Rarely, a malignant tumour may disappear spontaneously from the primary site, due to good host immune attack.
  • 26. Characteristics of tumours • Cancer phenotype and stem cells Cancer cells 1. disobey the growth control – proliferate rapidly 2. escape from death signals – immortality 3. imbalance between cell proliferation and cell death – excessive growth 4. lose differentiation properties – no function 5. are unstable – newer mutations 6. overrun their neighboring tissue – invade locally 7. have the ability to travel from the site of origin to other part of body – distant metastasis Cancer stem cells/ tumour-initiating cells have the properties of self-renewal, asymmetric replication and transdifferentiation (i.e. plasticity).
  • 27. Characteristics of tumours • Clinical and gross features – Benign tumour are generally slow growing and depending upon location remains asymptomatic (subcutaneous lipoma) or may cause serous symptoms (meningioma in the nervous system). Benign tumours are generally spherical or ovoid shape. – Malignant tumor grow rapidly, invade locally into deeper tissue and spread to distant sites (metastasis). Malignant tumours are usually irregular in shape, poor-circumscribed and extend into adjacent tissues.
  • 28. Characteristics of tumours • Microscopic features – Microscopic pattern – Cytomorphology of neoplastic cells – Tumor angiogenesis and stroma – Inflammatory reaction
  • 29. Characteristics of tumours • Local invasion (direct spread) – Benign: expand and push aside without invading, infiltrating or metastasising. – Malignant: expand, invasion, infiltration and destruction of the surrounding tissue. • Metastasis (distant spread) – Metastasis (meta= transformation, stasis= residence): spread of tumour by invasion. – Routes of metastasis • Lymphatic spread • Haematogenous spread • Spread along body cavities and natural passages
  • 30. Tumours grading Grading is based on (1) the degree of anaplasia (2) the rate of growth • Grade-I : Well-differentiated (less than 25% anaplastic cells) • Grade-II : Moderately-differentiated (25-50% anaplastic cells) • Grade-III : Moderately-differentiated (50-75% anaplastic cells) • Grade-IV : Poorly-differentiated or anaplastic (more than 75% anaplastic cells)
  • 31. Tumours staging • International TNM system is commonly used for solid tumours (less applicable to lymphomas and leukaemias). – T: Tumour (size of primary tumour), N: Nodes (local/ regional node involvement), M: Metastases (distant metastases) T0 No evidence of tumour N0 Regional lymph nodes not involved Tis Carcinoma in situ NX Regional lymph nodes can’t be assessed TX Tumour can’t be assessed N1-4 Progressive increase in number of local/ regional lymph nodes involved T1-4 Progressive increase in tumour size M0 No evidence of distant metastases MX distant metastases can’t be assessed M1-3 Increasing involvement of distant metastases